LBDA

Research Funding Announcements

Stay up-to-date on LBD-relevant funding opportunity announcements from federal agencies like the National Institutes of Health and Department of Defense.

NATIONAL INSTITUTES OF HEALTH

Title: Solicitation of Nominations for the 2020 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship
Notice Number: NOT-NS-19-080
Issued by: National Institute of Neurological Disorders and Stroke (NINDS)
Description: This award provides $100,000.00 (direct costs) to up to five (5) faculty members who are considered to be outstanding mentors and trainers to help foster the research career development of additional students and post-doctorates.  NINDS invites nominations of outstanding mentors who are 21 years or more from the start of their first tenure-track or equivalent faculty position (i.e., the start date of their first tenure-track or equivalent faculty position was in calendar year 1998 or earlier). Selection for this award is based on nomination from those who have first-hand knowledge of an individual's outstanding mentorship.
Application Due Date(s): Complete a nomination form by December 1, 2019
Funds Available and Anticipated Number of Awards: $100,000.00 (direct costs) to up to five (5) faculty members
Scientific/Research Contacts: Stephen Korn

 

Title: Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
Notice Number: PAR-19-302
Issued by: National Institute on Aging
Description This FOA provides a vehicle for submitting investigator-initiated grant applications to conduct multi-site clinical trials of all phases and stages on topics relevant to NIA's mission.
Open Date (Earliest Submission Date): September 05, 2019
Application Due Date(s): The first standard application due date for this FOA is October 5, 2019.
Expiration Date: September 08, 2022
Funds Available and Anticipated Number of Awards: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Award Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Award Project Period: The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Scientific/Research Contacts: Sergei Romashkan, M.D., Ph.D., Lisa Onken, Ph.D., Laurie Ryan, Ph.D.

 
 

Title: Transition to Aging Research Award for Predoctoral Students (F99/K00)
Notice Number: RFA-AG-20-009
Issued by: National Institute on Aging
Description: NIA invites outstanding graduate students from a wide range of broad research areas including, but not limited to, statistics, neuroscience, physics, immunology, microbiology, informatics, data sciences, and engineering who are interested in receiving aging-related postdoctoral training to apply for this award.
Open Date (Earliest Submission Date): September 22, 2019
Application Due Date(s): October 22, 2019
Scientific Merit Review: February/March 2020
Funds Available and Anticipated Number of Awards: NIA intends to commit $450,000 in FY 2020 to fund 7-10 awards.
Scientific/Research Contacts: Sergei Romashkan, M.D., Ph.D.

 

Title: Program Project Applications (P01 Clinical Trial Optional)
Notice Number: PAR-19-314
Issued by: National Institute on Aging
Description: The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission.
Open Date (Earliest Submission Date): August 9, 2019
LOI Date: 30 days prior to due date
First Standard Due Date(s): September 25, 2019.
Funds Available and Anticipated Number of Awards: Contingent upon NIH appropriations and the submission of meritorious applications.
Scientific/Research Contacts: Robin A. Barr, D. Phil.

 

Title: Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
Notice Number: PAR-19-315
Issued by: National Institute of Neurological Disorders and Stroke
National Institute on Aging
Description: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.
Open Date (Earliest Submission Date): August 9, 2019
LOI Date: 30 days prior to due date
Application Receipt Date(s): September 4, 2019; February 14, 2020; July 20, 2020; February 17, 2021; July 19, 2021; and February 14, 2022
Funds Available and Anticipated Number of Awards: Contingent upon NIH appropriations and the submission of meritorious applications.
Scientific/Research Contacts: Mary Ann Pelleymounter, PhD (NINDS), Julia Bachman, PhD,  (NINDS) Suzana Petanceska, Ph.D. (NIA)

 

Title: Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer's disease and Alzheimer's related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)
Notice Number: RFA-NS-20-004
Issued by: National Institute of Neurological Disorders and Stroke
National Institute on Aging
Description: The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.
Open Date (Earliest Submission Date): September 09, 2019
LOI Date: September 9, 2019
Application Due Date(s): October 9, 2019
Scientific/Research Contacts: Francesca Bosetti, Pharm.D., Ph.D.